期刊文献+

vimentin在三阴性乳腺癌中的表达及临床意义 被引量:3

Expression of vimentin in triple negative breast cancer and its clinical significance
下载PDF
导出
摘要 目的研究波形蛋白(vimentin)在人三阴性乳腺癌中的表达及意义。方法采用免疫组化和Westernblot检测122例三阴性人乳腺癌组织中vimentin表达,并分析其与临床病理特征及预后的关系;Westernblot分析三阴性乳腺癌细胞系MDA-MB-231与非三阴性乳腺癌细胞系MCF-7中vimentin的表达;Transwell侵袭试验检测细胞的侵袭能力。结果在122例三阴性人乳腺癌组织中vimentin表达明显高于对应的癌旁组织(P<0.05),同时vimentin的表达与其病理分化程度存在明显的相关性(P<0.05)。vimentin在三阴性乳腺癌细胞MDA-MB-231中呈高表达,而在非三阴性的MCF-7细胞中表达较低。结论三阴性乳腺癌细胞中vimentin表达增高,vimentin的表达可能与三阴性乳腺癌的侵袭和迁移有关。 Objective To study vimentin expression in human triple negative breast cancer(TNBC)and its clinical significance. Methods The expression of vimentin in 122 triple negative human breast cancer tissues were detected by using immunohistochemistry and western blot, and the relationship between clinical and pathological data was analyzed. The cell invasion ability was analyzed by transwell invasion assay. Results vimentin expression in 122 cases of triple negative human breast cancer tissues was significantly higher than that in the adjacent tissues (P0.05). There was obvious correlation between the expression of vimentin and pathologic differentiation (P0.05). Vimentin was highly expressed in TNBC cells MDA-MB-231,while it was lowly expressed in the non-TNBC MCF-7 cells. Conclusions Increased vimentin expression in TNBC cells may be associated with the TNBC invasion and migration.
出处 《实用老年医学》 CAS 2012年第6期466-469,共4页 Practical Geriatrics
关键词 三阴性乳腺癌 波形蛋白 侵袭 迁移 triple negative breast cancer(TNBC) vimentin invasion migration
  • 相关文献

参考文献14

  • 1Adamo B, Anders CK. Stratifying triple-negative breast cancer: which definition (s) to use? [J]. Breast Cancer Res, 2011,13(2) : 105.
  • 2Tan GH, Taib NA, Choo WY, et al. Clinical characteristics of triple-negative breast cancer: experience in an Asian developing country [J]. Asian Pac J Cancer Prey, 2009, 10 (3) : 395-398.
  • 3周涛,杨丽,马国明,李春晓,白杨,赵冀安,王小玲,耿翠芝.三阴性乳腺癌的临床特征及预后分析[J].中华医学杂志,2009,89(32):2261-2264. 被引量:12
  • 4Uematsu T, Kasami M, Yuen S. Triple-negative breast cancer: correlation between MR imaging and pathologic findings [J]. Radiology, 2009,250(3): 638-647.
  • 5Volmer C, Benal Y, Caplier L, et al. Atypical vimentin expression in a feline salivary gland adenocarcinoma with wide-spread metastases [ J ]. J Vet Med Sci, 2009,71 (12) : 1681-1684.
  • 6Shirahata A. Vimentin methylation as a marker for advanced colorectal carcinoma [ J ]. Anticancer Res, 2009,29 ( 1 ) : 279-281.
  • 7Schopferer, Bar H, Hochstein B, et al. Desmin and vimentin intermediate filament networks: their viscoelastic properties investigated by mechanical rheometry [ J ]. J Mol Biol, 2009,388( 1 ) : 133-143.
  • 8Rakha EA. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes [J]. Clin Cancer Res, 2009, 15(7) : 2302-2310.
  • 9Pal SK, Mortimer J. Triple-negative breast cancer: novel therapies and new directions [J]. Maturitas, 2009,63(4) : 269 -274.
  • 10Pan Y, Lei T, Teng B, et al. Role of vimentin in the inhibitory effects of low-molecular-weight heparin on PC-3M cell adhesion to, and migration through, endothelium [J]. J Pharmacol Exp Ther,2011,339(1): 82-92.

二级参考文献43

共引文献21

同被引文献45

  • 1王涛,江泽飞,宋三泰,张少华,申戈,于静新.单药希罗达治疗复发转移性乳腺癌的疗效观察[J].中华肿瘤杂志,2004,26(6):379-381. 被引量:57
  • 2孙燕,周际昌.临床肿瘤内科手册[M].4版.北京:人民卫生出版社,2003:568-569.
  • 3Miwa M,Nishida UM,Ishikawa ST,et al. Design of a navel oral fluoropyrimidine carbamate. Capecitabine. Which enerates 5- Fluorouracil selectively in tumors by engymes concentrated in human liver and cancer tissue [J]. Eur Cancer, 1998,34:1274- 1278.
  • 4Blum JL,Dieras V,Lo Russo PM,et al. Multicente,phrase II study of eapecitabien in taxane-pretreated metastastic breast carcinoma patients [J]. Cancer, 2001,92 : 1759-1767.
  • 5Blum JL,Jones SE,Buzdar AU,et al. Multicenter phase Ⅱ study of capecitabine in paclitaxel-refractory metastatic breast cancer [J]. J Clin Oncol, 1999,17:485-493.
  • 6Talbot DC,Moiseyenko V,Van Belle S,et al. Randomised,phase Ⅱ trial comparing oral capecitabine (Xeloda)with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines [J]. Br J Cancer, 2002,86:1367-1372.
  • 7Siege 1R, Naishadham D, Jemal A. Cancer statistics, 2013 [ J]. CA Cancer Journal for Clinicians,2013,63 ( 1 ) :11-30.
  • 8Enserink M. A push to fight cancer in the developing world [ J ]. Sci- ence,2011,331 (6024) :1548-1550.
  • 9Zhang Y, Liao JM, Zeng SX, et al. p53 downregnlates Down syndrome- associated DYRK1A through miR-1246 [ J ]. EMBO Reports, 2011,12 (8) :811-$17.
  • 10Liao JM,Zhou X,Zhang Y, et al. MiR-12g6: a new link of the p53 family with cancer and Down syndrome [ J ]. Cell Cycle, 2012, 11 (lg) :2624-2630.

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部